Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment of mood disorders

Abstract

Depression is a leading cause of morbidity and mortality, and its treatment includes a high percentage of the medications prescribed by physicians. Available antidepressant drugs are safe and effective, but less than half of all patients attain complete remission after therapy with a single antidepressant. Others exhibit partial, refractory or intolerant responses to treatment, emphasizing the need to discover new antidepressants. The mechanisms of action of available medications are directing the field toward new research avenues. This review highlights those areas we believe will influence the field and soon lead to better treatment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kessler, R.C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry 51, 8–19 (1994).

    Article  CAS  Google Scholar 

  2. Blazer, D.G. et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151, 979–986 (1994).

    Article  CAS  Google Scholar 

  3. Murray, C.J.L. & Lopez, A.D. (eds.) The Global Burden of Disease (Harvard Univ. Press, Boston, 1996).

    Google Scholar 

  4. Klerman, G.L. et al. Birth-cohort trends in rates of major depressive disorder among relatives of patients with affective disorder. Arch. Gen. Psychiatry 42, 689–693 (1985).

    Article  CAS  Google Scholar 

  5. Musselman, D.L., Evans, D.L. & Nemeroff, C.B. The relationship of depression to cardiovascular disease: diagnosis, biology and treatment. Arch. Gen. Psychiatry 55, 580–592 (1998).

    Article  CAS  Google Scholar 

  6. Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression following myocardial infarction: impact on 6-month survival. JAMA 270, 1819–1825 (1993).

    Article  CAS  Google Scholar 

  7. Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression and 18-month prognosis after myocardial infarction. Circulation 91, 999–1005 (1995).

    Article  CAS  Google Scholar 

  8. Sanders, A.R., Detera-Wadleigh, S.D. & Gershon, E.S. in Neurobiology of Mental Illness (eds. Charney, D. S., Nestler, E. J. & Bunne,y B. S.) 299–316 (Oxford Univ. Press, New York, 1999).

    Google Scholar 

  9. Duman, R.S., Heninger, G.R. & Nestler, E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597–606 (1997).

    Article  CAS  Google Scholar 

  10. Thome, J. et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 4030–4036 (2000).

    Article  CAS  Google Scholar 

  11. Entsuah, A.R., Huang, H. & Thase, M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869–877 (2001).

    Article  CAS  Google Scholar 

  12. Thase, M.E., Entsuah, A.R. & Rudolph, R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234–241 (2001).

    Article  CAS  Google Scholar 

  13. Owens, M.J. & Nemeroff, C.B. The serotonin transporter and depression. Depress. Anxiety 8(S1), 5–12 (1998).

    Article  Google Scholar 

  14. Ressler, K.J. & Nemeroff, C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46, 1219–1233 (1999).

    Article  CAS  Google Scholar 

  15. Meyer, J.H. et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 12, 4121–4125 (2001.)

    Article  CAS  Google Scholar 

  16. Anderson, I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disorders 58, 19–36 (2000).

    Article  CAS  Google Scholar 

  17. Gilmor, M.L., Owens, M.J. & Nemeroff, C.B. Inhibition of norepinephrine uptake in patients with major depression treated with the selective serotonin reuptake inhibitor paroxetine. Am. J. Psychiatry (in press).

  18. Owens, M.J. et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305–1322 (1997).

    CAS  PubMed  Google Scholar 

  19. Blier, B. Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psychiatry 62(S15), 12–17 (2001).

    Google Scholar 

  20. Rabiner, E.A. et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry 158, 2080–2082 (2001).

    Article  CAS  Google Scholar 

  21. Owens, M.J. & Nemeroff, C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43, 425–473 (1991).

    CAS  PubMed  Google Scholar 

  22. Reul, J.M. & Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23–33 (2002).

    Article  CAS  Google Scholar 

  23. Zobel, A.W. et al. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatry Res. 34, 171–181 (2000).

    Article  CAS  Google Scholar 

  24. Belanoff, J.K., Flores, B.H., Kalezhan, M., Sund, B. & Schatzberg, A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21, 516–521 (2001).

    Article  CAS  Google Scholar 

  25. Kramer, M.S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645 (1998).

    Article  CAS  Google Scholar 

  26. Stout, S.C., Owens, M.J. & Nemeroff, C.B. Neurokinin1 receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. 41, 877–906 (2001).

    Article  CAS  Google Scholar 

  27. Meyer, J.H. et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am. J. Psychiatry 158, 1843–1849 (2001).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported by NIH grants MH42088, MH39415 and the Conte Center for the Neuroscience of Mental Disorders (MH58922).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charles B. Nemeroff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nemeroff, C., Owens, M. Treatment of mood disorders. Nat Neurosci 5 (Suppl 11), 1068–1070 (2002). https://doi.org/10.1038/nn943

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nn943

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing